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The growth hormone (GH) and insulin-like growth fac-
tor I (IGF-I) axis were studied in streptozotocin (STZ) di-
abetic and nondiabetic female mice following intravenous
(IV) injection of the GH secretagogue (GHS) ipamorelin or
saline. On day 14, blood samples were obtained before and
10 minutes after the injection. Livers were removed and
frozen for determination of the mRNA expressions of the
GH receptor, GH-binding protein, and IGF-I, and hepatic
IGF-I peptide. Serum samples were analyzed for GH and
IGF-I. Following ipamorelin injection, the GH levels were
found to be 150 ± 35 µg/L and 62 ± 11 µg/L in the diabetic
compared to the nondiabetic mice (P <.05). Serum IGF-I
levels were lower in diabetic than in nondiabetic animals,
and rose after stimulation only in the nondiabetic animals.
Furthermore, hepatic GH resistance and IGF-I mRNA lev-
elsandIGF-Ipeptidewereincreasedinnondiabeticanimals
in response to GHstimulation,whereas the low levels per se
ofalltheseparametersindiabeticmicewereunaffected.The
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studyshowsthatSTZdiabeticmicedemonstrateasubstan-
tialpartoftheclinicalfeaturesoftype1diabetesinhumans,
including GH hypersecretion and GH resistance. Accord-
ingly, it is proposed that STZ diabetic mice may be a better
modeloftheperturbationsoftheGH/IGF-Iaxisindiabetes
than STZ diabetic rats.
Keywords Diabetes; Growth Hormone Resistance; Growth
Hormone Secretion; Insulin-Like Growth Factors;
Ipamorelin; Mice; Streptozotocin
Growth hormone (GH) and insulin-like growth factors
(IGFs)havealonghistoryindiabetesmellitus,withconceivable
effects on the development of diabetic renal complications; for
review, see [1–4]. Poorly controlled type 1 diabetes in man is
characterized by GH hypersecretion and low circulating IGF-I
levels [5–8]. The streptozotocin (STZ) diabetic rat, however,
is characterized by suppressed serum GH levels and loss of
the characteristic pulsatility [9–11]. It has been reported that
pituitary GH concentration is signiﬁcantly reduced in STZ dia-
betic rats as compared to that observed in control animals. The
reduced GH levels are probably due to a deﬁciency in GH stor-
age and/or synthesis [12]. Both increased [13] and decreased
[14] GH levels have been found in the Biobred (BB) rat, which
is considered to be the classical model of early (autoimmune)
onset type 1 diabetes.
The highly conspicuous species difference in neuroregula-
tion of the GH axis in diabetes is also present during other
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exogenous stimuli, such as exercise, starvation, and stress; for
review, see [15]. To be able to extent results obtained in ani-
mal studies into humans, it is imperative that the animal model
closely reﬂects the clinical condition. In the present paper, we
show enhancement of GH secretion also in STZ diabetic mice
following intravenous (IV) injection of the GH secretagogue
(GHS) ipamorelin.
MATERIALS AND METHODS
Animals and Protocol
FourgroupsofadultfemaleBalb/C(a)mice(Bomholtgaard,
Ry, Denmark), with initial body weights of 15 to 19 g, were
studied. The mice were housed 6 to 8 per cage in a room with
12:12-hour light cycle, temperature 21◦C±2◦C and humid-
ity 55%±2%. The animals had free access to standard chow
(Altromin no. 1324, Lage, Germany) and tap water through-
out the experiment. The animals were randomly allocated to
4 groups, and 2 of these groups were made diabetic by a sin-
gle IV injection of STZ (Upjohn Company, Kalamazoo, MI,
USA), in a dose of 300 mg/kg body weight. The development
of diabetes was followed over the next 14 days by measur-
ing blood glucose by Haemoglucotest 1-44 and Reﬂolux II re-
ﬂectancemeter(Boehringer-Mannheim,Mannheim,Germany)
and urine for glucose and ketone bodies by Neostix-4 (Ames,
Stoke Poges, Slough, UK). Only animals with blood glucose
above 16 mmol/L, glucosuria above 111 mmol/L, and without
ketonuria were included in the study. Body weight and food
consumption were recorded.
At day 14, ipamorelin, 200 µg/kg, or saline, 5 mL/kg, were
injected intravenously. Blood was drawn before and exactly 10
minutes after the injection from the retro-orbital venous plexus
fordeterminationofserumGH,IGF-I,andIGF-bindingprotein
3 (IGFBP-3). Serum was stored at −80◦C until measurements
were performed. Furthermore, the kidneys and livers were
rapidly removed and carefully cleaned and weighed. The livers
were frozen in liquid nitrogen and stored at −80◦C for later
determination of the mRNA of the GH receptor (GHR), GH-
binding protein (GHBP), and IGF-I, and hepatic IGF-I peptide.
The study was performed under an approved animal per-
mit complying with national regulations for use of animals in
research (the Danish Animal Inspectorate).
Immunoassays
Serum GH was measured by radioimmunoassay (RIA) us-
ing a speciﬁc polyclonal rabbit rat(r) GH antibody and rGH
as standard. Semilog linearity of mouse serum and rGH (in
the standard) was found at multiple dilutions, indicating anti-
gen similarity between mouse GH and rGH. The ingredients,
including [125I]-rGH, were obtained from Amersham Interna-
tional, Bucks, UK. Serum IGF-I was measured after extraction
with acid-ethanol. The mixture was incubated for 2 hours at
room temperature, centrifuged, and 25 µL of the supernatant
was diluted 1:200 before analysis. Liver extraction was per-
formed as previously described [16]. Brieﬂy, 80 to 100 mg
of liver tissue was homogenized on ice in 1 M acetic acid
(5 mL/g tissue) with an Ultra Turrax TD 25 and further dis-
rupted using a Potter Elvehjelm homogenizer. An additional
extractionprocedure(withethanol/HCl)wasperformedinliver
homogenates to fully remove all IGFBPs. After lyophilization,
the samples were redissolved in phosphate buffer (pH 8.0) and
kept at −80◦C until the IGF-I assay was performed in diluted
extracts. Serum and liver IGF-I levels were measured by RIA
using a polyclonal rabbit antibody (Nichols Institute Diagnos-
tics, San Capistrano, CA, USA) and recombinant human IGF-I
asstandard(AmershamInternational).ThetissueIGF-Iconcen-
trations were corrected for the contribution of entrapped serum
IGF-I [16]. Monoiodinated IGF-I ([125I-Tyr31]-IGF-I) was ob-
tainedfromNovoNordiskA/S,Bagsværd,Denmark.Intra-and
interassay coefﬁcients of variations for both assays were <5%
and <10%, respectively, for both assays.
Western Ligand Blotting (WLB)
for Determination of Serum IGFBP-3
Sodium dodecyl sulfate–polyacrylamide gel electrophore-
sis (SDS-PAGE) and WLB were performed according to the
method of Hossenlopp and colleagues [17] as previously de-
scribed [18]. Two microliters of serum was subjected to SDS-
PAGE (10% polyacrylamide) under nonreducing conditions.
The electrophoresed proteins were transferred by electroelu-
tion onto nitrocellulose paper (Schleicher & Schuell, Munich,
Germany) and membranes were incubated overnight at 4◦C
with approximately 500,000 cpm [125I]-IGF-I (speciﬁc activity
2000 Ci/mmol) in 10 mL 10 mmol/L Tris-HCl buffer (TBS)
containing 1% bovine serum albumin (BSA) and 0.1% Tween
(pH 7.4). Membranes were washed with TBS and after dry-
ing overnight, the nitrocellulose sheets were autoradiographed
with Kodak X-AR ﬁlm and exposed to Du Pont–New England
Nuclear enhancing screens at −80◦C for 3 to 7 days. Speci-
ﬁcityoftheIGFBPbandswasensuredbycompetitivecoincuba-
tionwithunlabeledIGF-IpurchasedfromBachem(Bubendorf,
Switzerland). On WLB (with [125I]-IGF-I as ligand), IGFBP-3
appear as a 38- to 42-kDa doublet band corresponding to the
intact acid-stable IGF-binding subunit of IGFBP-3. Western
ligand blots were quantiﬁed by densitometry using a Shimadzu
CS-9001 PC dual-wavelength ﬂying spot scanner.
GHR/GHBP and IGF-I mRNA
Total RNA was prepared from frozen tissue by Tri reagent
(Molecular Research Center, Cincinnati, OH, USA) andGH HYPERSECRETION IN STZ DIABETIC MICE 75
TABLE 1
Body weight, blood glucose, food consumption, kidney weight (both kidneys), and liver weight in nondiabetic mice injected
with saline (C/SAL) or ipamorelin (C/IPA) and diabetic animals injected with saline (D/SAL) or ipamorelin (D/IPA) at day 14
Body weight Blood glucose Food consumption Kidney weight Liver weight
(g) (mM) (g/day) (mg) (mg)
C/SAL 20.2±0.4 6.1±0.4 5.4±0.9 245±3 1178±46
C/IPA 19.9±0.3 5.9±0.5 5.9±0.5 244±6 1074±51
D/SAL 15.2±0.3∗ 22.8±0.7∗ 9.2±0.8∗ 269±6∗ 898±38∗
D/IPA 15.5±0.4∗ 23.8±1.0∗ 9.6±0.9∗ 264±6∗ 902±76∗
Note. Values are means±SEM, n=7–10 per group.
∗P <. 01 versus respective control groups (Student’s t test for unpaired comparisons).
quantiﬁed by absorbency at 260 nm. The integrity of the RNA
was assessed by visual inspection of the ethidium bromide–
stained 28S and 18S RNA bands after electrophoresis through
1.25%/2.2 M formaldehyde gels. For Northern blot analysis,
20 µg of total RNA were electrophoresed on 1.3% agarose/
2.2 M formaldehyde gels in 3-morpholinopropanesulphonic
acid buffer. The RNA was then transferred onto Magna-
Graph (MSI, Westboro, MA, USA) nylon membranes and
was cross-linked to the membrane with an ultraviolet (UV)
cross-linker(HoeferScientiﬁcInstruments,SanFrancisco,CA,
USA). A rat GHR/GHBP probe (a generous gift from L.
Mathews)wasradiolabeledwith[32P]-dCTP(AmershamInter-
national) by a random-primed DNA labeling kit (Boehringer-
Mannheim). RNA hybridization was performed in a hybridiza-
tion oven (Micro-4; Hybaid Ltd, UK) at 65◦C for 20 hours
in a hybridization solution (0.2 mM Na2HPO4, pH 7.2, 7%
[vol/vol] SDS, 1% [wt/vol] BSA, and 1 mM EDTA). Gels
were exposed to Kodak X-Omat AR ﬁlm at −70◦C with
two intensifying screens. The autoradiograms were quan-
tiﬁed using a phosphoimager (Imagequant; Molecular Dy-
namics, Sunnyvale, CA, USA). IGF-I mRNA levels were
determined using a solution hybridization/RNase protection
assay. In brief, 25 µg of total RNA was hybridized with
400,000 cpm of 32P-labeled riboprobe for 16 hours at 45◦C
in 75% formamine–0.4 M NaCl, followed by digestion with
40 g/L RNase T1. Protected hybrids were precipitated, dena-
tured, and electrophoresed through 8% urea–polyacrylamide
gels. Gels were exposed to Kodak X-Omat AR ﬁlm as de-
scribed above, and the protected band (231 bp) on the autora-
diography that corresponds to IGF-I was analyzed. The autora-
diograms were quantiﬁed using a phosphoimager as described
above.
Statistics
Student’s t test for unpaired comparisons was used. A P
value of less than 5% was regarded as signiﬁcant. Means ±
SEM are given.
RESULTS
Body Weight, Metabolic Parameters, and Food
Consumption
At day 14, the STZ-treated mice were markedly diabetic,
with blood glucose levels 4-fold higher than those of the con-
trol mice. Also, food consumption and kidney weight were in-
creased, and liver weight was decreased in the STZ diabetic
mice (Table 1).
Serum GH, IGF-I, and IGFBP-3
NodifferenceswereobservedinthebasalGHlevels.Follow-
ingGHSstimulation,however,theserumGHlevelswerefound
to be 150 ± 35 and 62 ± 11 µg/L, respectively, in the diabetic
compared with the nondiabetic animals (P <.05) (Figure 1).
Differences in the basal serum IGF-I levels were observed be-
tweenthediabeticandnondiabeticanimals,being208±23and
418±22µg/L,respectively(P <.0001).Afterstimulation,the
serum IGF-I level did not change in the diabetic treated ani-
mals,butincreasedto522±30µg/Linthenondiabeticanimals
(P <.01).
A representative autoradiogram of the IGFBP-3 WLB is
shown in Figure 2A. The IGFBP-3 levels were lower in dia-
betic as compared to nondiabetic animals, but ipamorelin stim-
ulation did not induce any changes neither in diabetic nor in
nondiabetic animals (Figure 2B).
Hepatic GHR/GHBP mRNA, IGF-I mRNA,
and IGF-I Peptide
Autoradiograms of the ethidium bromide staining of the
RNA samples before their transfer to the membrane and the
Northern blot analysis for the GHR and GHBP mRNAs are
shown in Figures 3A and 3B, respectively. Despite the fact that
the basal GH levels were comparable in diabetic and nondia-
betic animals, a signiﬁcant lower GHR mRNA expression was
found in the diabetic animals. After ipamorelin injection, the
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FIGURE 1
Serum growth hormone (GH) concentrations (µg/L) in nondiabetic mice injected with saline (C/SAL) or ipamorelin (C/IPA)
and diabetic animals injected with saline (D/SAL) or ipamorelin (D/IPA) 10 minutes after injection at day 14. Values are
means±SEM, n=7–8. #P <. 05 compared with C/IPA; ++P <. 01 compared with C/SAL. Student’s t tests for unpaired
comparisons were used.
animals. Also, GHBP mRNA levels were lower in diabetic
animals,buttheexpressionwasunchangedbyipamorelinstim-
ulation. IGF-I mRNA expression and hepatic IGF-I peptide
concentrations were increased by ipamorelin stimulation in
the nondiabetic animals, whereas no changes were induced in
the diabetic animals. The quantitative Northern blot analysis is
shown in Figure 4.
DISCUSSION
Poorlycontrolledtype1diabetesinhumansischaracterized
by GH hypersecretion [6, 8], whereas GH secretion in diabetic
rats is decreased [10, 11]. There is, on the other hand, support
for the contention that the difference between experimental di-
abetes in rats and human diabetes, with respect to the GH/IGF
axis, is restricted to GH. Accordingly, identical changes have
been reported for the other elements in the axis in diabetic rats
andman,includingchangesincirculatinglevelsofGHBP,IGF-
I,andIGFBPs;forreview,see[19].Also,disturbedhepaticand
renal transcriptional changes and decreased hepatic GHR num-
ber are well-described features in experimental diabetes in rats
[20–23].
The major new ﬁnding of the present study is the demon-
stration of GH hypersecretion in STZ diabetic mice after a GH
stimulation test using the GHS ipamorelin. After GHS stimula-
tion,a2-to3-foldincreaseinserumGHlevelswasevidentinthe
diabetic mice when compared to the nondiabetic control mice.
The sampling time was chosen from studies in rats and mice
where the systemic GH levels were shown to peak 10 minutes
after IV injection of ipamorelin [24, 25]. Ipamorelin belongs to
a class of peptide compounds that have been demonstrated to
possessadualactionatthepituitaryaswellasthehypothalamic
levels.Thus,GHSprovokesthereleaseofGHRHintohypophy-
seal portal blood [26], and it was recently reported that passive
immunizationwithanti-GHRHserumalmostcompletelyoblit-
erated the GH response to GHRP-6 [27]. These data clearly
demonstrate that the vast majority of the GH secretion after
GHS stimulation in vivo is caused by the release of GHRH.GH HYPERSECRETION IN STZ DIABETIC MICE 77
(A)
(B)
FIGURE 2
(A) Representative Western ligand blot (WLB) autoradiogram of serum samples from nondiabetic mice injected with saline
(C/SAL) (lanes 1 and 2) or ipamorelin (C/IPA) (lanes 5 and 6) and diabetic mice injected with saline (D/SAL) (lanes 3 and 4) or
ipamorelin (D/IPA) (lanes 7 and 8). Serum IGFBP-3 appears as a 38- to 42-kDa doublet band corresponding to the intact
acid-stable IGF-binding subunit of IGFBP-3. Mr, molecular weight. (B) Quantitative analysis of serum insulin-like growth
factor I (IGF-I) concentrations (µg/L) and IGF-binding protein 3 (IGFBP-3) levels (pixel) in nondiabetic mice injected with
saline (C/SAL) or ipamorelin (C/IPA) and diabetic animals injected with saline (D/SAL) or ipamorelin (D/IPA) 10 minutes after
injection at day 14. Values are means±SEM, n=7–8. ∗P <. 02 compared with C/SAL; +P <. 0001 compared with C/SAL;
++P <. 0001 compared with C/IPA. Student’s t tests for unpaired comparisons were used.78 P. B. JOHANSEN ET AL.
(A)
(B)
FIGURE 3
(A) Ethidium staining of the RNA samples before their transfer to the membrane. The locations of the 28S and 18S ribosomal
RNA bands are depicted. (B) Northern blot analysis of liver total RNA (20 µg) from nondiabetic mice injected with saline
(C/SAL) (lanes 1 to 3) or ipamorelin (C/IPA) (lanes 4 to 7) and diabetic mice injected with saline (D/SAL) (lanes 8 to 10) or
ipamorelin (D/IPA) (lanes 11 to 14). The 4.4-kb and 1.2-kb bands corresponding to the GHR and GHBP are shown on the left.
The elevated stimulated serum GH in diabetic mice is con-
trary to previous reports on the usual model of animal type 1
diabetes,theSTZdiabeticrat.Inthisanimal,decreasedGHlev-
els have been described, probably due to the inhibition of GH
release from the pituitary [11]. It should be noted, however,
that the diabetic state in the present study and in all studies in-
vestigating GH secretion in rats have used a single high-dose
STZ injection. Induction of type 1 diabetes in rats or mice can
also be carried out by repeated daily low-dose STZ injections,
which are less likely to give kidney toxicity and ketosis-prone
diabetes. In the present study, however, the mice had a sta-
ble B-glucose without signs of ketosis. It has previously been
demonstrated that a single high-dose STZ injection does not
inﬂict kidney toxicity per se, except for the well-known kidney
changes caused by the diabetic state [16]. Whether a difference
in GH affection exists between the 2 STZ regimens remains to
be shown.
The stimulated GH levels of the nondiabetic mice were
accompanied by increases in circulating and hepatic IGF-I
peptide and mRNA levels. These changes were absent in theGH HYPERSECRETION IN STZ DIABETIC MICE 79
FIGURE 4
Quantitative analysis of hepatic GHR, GHBP, IGF-I mRNA (pixel), and hepatic IGF-I peptide (ng/g) levels in nondiabetic mice
injected with saline (C/SAL) or ipamorelin (C/IPA) and diabetic animals injected with saline (D/SAL) or ipamorelin (D/IPA)
10 minutes after injection at day 14. Values are means±SEM, n=3–4. ∗P <. 002 compared with C/SAL; +P <. 0002
compared with C/SAL; ++P <. 0001 compared with C/IPA; #P <. 05 compared with C/SAL;
§P <. 0005 compared with C/IPA.
Student’s t tests for unpaired comparisons were used.
diabeticanimals.Traditionally,themajorityofcirculatingIGF-I
is synthesized in the liver, mainly under the control of circu-
lating GH, and thus in hyperglycemic diabetic subjects, serum
IGF-I is reduced in spite of elevated GH. In order to explain
this phenomenon, it has been hypothesized that the diabetic
metabolic deterioration ﬁrst decreases hepatic IGF-I formation
andserumIGF-Ilevels,whichthensecondarilyinducesGHhy-
persecretion [1, 3, 5–8]. This hypothesis is in accordance with
the ﬁndings of the present study, and is in agreement with re-
sults obtained in recent studies in diabetic mice [3, 16, 28]. GH
receptor resistance has been suggested by previous clinical and
experimental studies in type 1 diabetes. The previous ﬁndings
include(a)decreasedliverGHBPindiabeticstates;(b)reduced
plasma concentrations of GHBP in untreated spontaneously di-
abetic BB rats with full normalization during insulin adminis-
tration[23];(c)decreasedserumGHBPinhumanpatientswith
insulin-dependent diabetes mellitus (IDDM) [29]; and (d) re-
duced IGF-I secretion associated with low hepatic GHR levels,
which also normalize during insulin treatment [30].
To our knowledge, only one study has addressed the GH
proﬁle in conscious STZ diabetic mice ﬁtted with indwelling
catheters [31]. In this study, suppression of episodic GH
secretion was reported. The pituitary GH responses in vitro to
different doses of GHRH, however, were found to be remark-
ably increased, suggesting an up-regulation of the pituitary
GHRH receptor caused by a decrease in hypothalamic GHRH
secretion. Also, the pituitary GH content was reduced. If the
reduced GH levels in vivo were caused by decreased GHRH
synthesis/release, the enhanced GH secretion following GHS
stimulation in the present study is difﬁcult to explain, because80 P. B. JOHANSEN ET AL.
the GH release following GHS stimulation is predominantly
conveyed by GHRH. One conspicuous difference between the
2 studies was found in the blood glucose levels (32 versus
24 mmol/L), suggesting that the diabetic aberration had been
more severe in the study by Murao and colleagues [31]. It
can be speculated that the differences in GH levels are due to
differences in diabetic aberration. Of note, no differences in
the basal GH levels were observed in the present study. This
is contrary to the ﬁndings in nonobese diabetic (NOD) mice
[28].
Recent studies have described renoprotective effects of GH
antagonists in long-term diabetic transgenic mice that express
theGHantagonistsbGH-G119RandhGH-G120R[16,32,33].
Also, normalization of diabetic renal and glomerular hypertro-
phy, along with a reduction in the diabetes-associated increase
in urine albumin excretion, have been reported in diabetic mice
treated with the GH antagonist G120K-PEG [16, 34]. These
observations are in agreement with the present ﬁnding of GH
hypersecretion in STZ diabetic mice and that GH (and IGFs)
is involved in the pathogenesis of diabetic kidney disease in
experimental diabetes.
Inconclusion,thepresentpaperreportsenhancedGHsecre-
tion in STZ diabetic mice when compared to nondiabetic mice
following stimulation with a GH secretagogue. Consequently,
theSTZdiabeticmouseseemstoreﬂectbettertheperturbations
of the circulating GH/IGF levels as seen in human type 1 dia-
betes, and may be a more suitable model than the STZ diabetic
rat. As only few studies on GH secretion in STZ diabetic mice
have been published, more extended studies on this topic are
highly warranted.
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